Halozyme Therapeutics' net profit under GAAP for 6 months of 2020 amounted to $19,714 million compared to a loss of $12,828 million in the previous year. Revenue decreased by 16.2% to $80,575 million compared to $96,097 million a year earlier.
Halozyme Therapeutics' net profit under GAAP for 6 months of 2020 amounted to $19,714 million compared to a loss of $12,828 million in the previous year. Revenue decreased by 16.2% to $80,575 million compared to $96,097 million a year earlier. 
halozyme.com
English (US) 